A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index


About AtheroGenics:

AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma.

AtheroGenics currently has two v-protectant® programs in clinical development targeting atherosclerosis and organ transplant rejection.


V -Protectants® Block Activation of VCAM-1 in cells that line blood vessels.

V-Protectants® are drugs that block a class of signals, called oxidant signals, which are generated within endothelial cells. These oxidant signals activate genes, which produce inflammatory proteins. The protein products of these selected genes, including VCAM-1, attract white blood cells to the site of chronic inflammation. This mechanism within arterial blood vessel walls may control the excessive accumulation of white blood cells without affecting the body's ability to fight infection




Clinical Trial Data -- Lead Compound
Atherosclerosis Coronary Artery Disease Myocardial Infarction Unstable Angina
Drug: AGI-1067
Phase III

NIH Link


More on Atherogenics

Home Page

Key Statistics fo Atherogenics

Basic Chart for Atherogenics

Analyst Opinion

Analysts Estimates

Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.